Galactomannan-Based and PCR-Based Assays in Bronchoalveolar Lavage to Diagnose Invasive Aspergillosis: Current Status and Future Prospects

Invasive pulmonary aspergillosis (IPA) is a life-threatening complication in patients receiving chemotherapy or undergoing allogeneic haematopoietic stem cell transplantation for acute leukemia. The existing tools to diagnose IPA lack specificity or sensitivity, or both; the search for improved diagnostic tools for IPA has focused on novel serologic and molecular methods. Aspergillus Galactomannan enzyme-linked immunosorbent assay (GM) analyses showed sensitivity rates in serum samples ranging in a wide span; testing GM in bronchoalveolar lavage (BAL) originated from the primary site of the infection seems to be more sensitive in patients with IPA. Other novel diagnostic markers to detect fungal DNA directly in clinical samples, rapidly, early, sensitively and specifically, are provided by polymerase chain reaction (PCR) based assays; higher sensitivity and specificity rates have been observed for BAL samples in IPA, even under antifungal treatment. The clinical place value of a diagnostic approach combining PCR and GM in BAL is unclear.     

Evaluation of Commercially Available Real-Time Polymerase Chain Reaction Assays for the Diagnosis of Invasive Aspergillosis in Patients with Haematological Malignancies

Mycopathologia - Early diagnosis of invasive aspergillosis (IA) is a challenge. Non-specific clinical and radiologic findings, as well as difficulties in conventional diagnostic method application,...     

Detection of Urinary Excreted Fungal Galactomannan-like Antigens for Diagnosis of Invasive Aspergillosis

Mortality associated with invasive aspergillosis (IA) remains high, partly because of delayed diagnosis. Detection of microbial exoantigens, released in serum and other body fluids during infection, may help timely diagnosis. In course of IA, Aspergillus galactomannan (GM), a well established polysaccharide biomarker, is released in body fluids including urine. Urine is an abundant, safely collected specimen, well-suited for point-of-care (POC) testing, which could play an increasing role in screening for early disease. Our main objective was to demonstrate GM antigenuria as a clinically relevant biological phenomenon in IA and establish proof-of-concept that it could be translated to POC diagnosis. Utilizing a novel IgM monoclonal antibody (MAb476) that recognizes GM-like antigens from Aspergillus and other molds, we demonstrated antigenuria in an experimental animal IA model (guinea pig), as well as in human patients. In addition, we investigated the chemical nature of the urinary excreted antigen in human samples, characterized antigen detection in urine by immunoassays, described a putative assay inhibitor in urine, and indicated means of alleviation of the inhibition. We also designed and used a lateral flow immunochromatographic assay to detect urinary excreted antigen in a limited number of IA patient urine samples. In this study, we establish that POC diagnosis of IA based on urinary GM detection is feasible. Prospective studies will be necessary to establish the performance characteristics of an optimized device and define its optimal clinical use.     

Current Status of Targets and Assays for Anti-HIV Drug Screening

HIV/AIDS is one of the most serious public health challenges globally. Despite the great efforts that are being devoted to prevent,treat and to better understand the disease,it is one of the main causes of morbidity and mortality worldwide. Currently,there are 30 drugs or combinations of drugs approved by FDA. Because of the side-effects,price and drug resistance,it is essential to discover new targets,to develop new technology and to find new anti-HIV drugs. This review summarizes the major targets and assays currently used in anti-HIV drug screening.     

Invasive Aspergillosis: Resistance to Antifungal Drugs

Although the arsenal of agents with anti-Aspergillus activity has expanded over the last decade, mortality due to invasive aspergillosis remains unacceptably high. Resistance of the Aspergillus spp. species to antifungal drugs increased in the last 20 years with the increase in antifungal drugs use and might partially account for treatment failures. Recent advances in our understanding of mechanisms of antifungal drug action in Aspergillus, along with the standardization of in vitro susceptibility testing methods, have brought resistance testing to the forefront of clinical mycology. Recent modifications in taxonomy and understanding of the acquired resistance mechanisms of Aspergilli to drugs should support a better management of Aspergillus infections. In this paper, we review the current knowledge on epidemiology and underlying mechanisms involved in antifungal resistance in Aspergillus.     

Azole-Resistant Invasive Aspergillosis: Relationship to Agriculture

Azole resistance in Aspergillus fumigatus has been increasingly reported particularly over the last decade. Two routes of acquisition are described: selection of resistance during long term azole therapy in the clinical setting, and primary acquisition of resistant isolates from the environment due to the considerable use of azole fungicides in agriculture and for material preservation. Three specific resistance genotypes have been found in azole naïve patients. Two of these have also been found in the environment and are characterized by a tandem repeat in the promoter region of the target gene coupled with point mutation(s) in CYP51A (TR₃₄/L98H and TR₄₆/Y121F/T289A). In the third a single target enzyme alteration (G432S) is found. These resistant “environmental” strains have been detected in many West-European countries as well as in the Asia-Pacifics. Noticeably, these two continents account for the highest fungicide use in the global perspective (37 % and 24 %, respectively). Among the 25 azole fungicides, five have been associated with the potential to select for the TR₃₄/L98H genotype; three of these are among those most frequently used. Although the number of antifungal fungicide compounds and classes available is impressive compared to the armamentarium in human medicine, azoles will remain the most important group in agriculture due to superior field performance and significant resistance in fungal pathogens to other compounds. Hence, further spread of environmental resistant Aspergillus genotypes may occur and will depend on the fitness of each resistant phenotype and the pattern of azole fungicide use.     

The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children

Invasive aspergillosis (IA) is a feared opportunistic infection for many immuncompromised children resulting in significant morbidity and mortality. Timely diagnosis based on traditional testing modalities and clinical evaluation has proven to be challenging. Assays designed to measure IA biomarkers such as galactomannan (GM) and beta-D-glucan (BG) represent a potential significant improvement in the ability to diagnose pediatric IA. However, as with any new diagnostic tool, clinicians need to be aware of the operating characteristics of these assays in order to apply them in the appropriate settings. Published adult and pediatric data regarding GM and BG testing are reviewed and guidance regarding the appropriate utility of these assays in children is offered.     

Pathogenesis and Pathology of Invasive Aspergillosis

Purpose of Review

Invasive aspergillosis occurs in immunosuppressed individuals and is associated with high morbidity and mortality. Understanding the host defenses and pathogen characters is important in the causation of disease.

Recent Findings

Neutropenia and/or corticosteroid administration increase the risk of invasive infections and majority are due to Aspergillus fumigatus. The size of the conidia, thermotolerance, hydrophobins and melanin on conidial surface, adaptability to host environment, and angioinvasive nature contribute to pathogenecity. The large conidial size, hot and humid environment, and constant exposure to high spore content are implicated in the pathogenesis of chronic invasive infections in a normal host due to Aspergillus flavus. Pathology depends on the immune status and varies from granuloma with fibrosis or suppuration to abscess or infarction.

Summary

The risk factors and the interplay of host pathogen in the pathogenesis of invasive aspergillosis are reviewed. Genetic predisposition and identification of such genetic factors are necessary for prevention and treatment.

     

Prophylaxis Versus a Preemptive Approach for Invasive Aspergillosis

Difficulty in making an early diagnosis of invasive aspergillosis and consequent poor clinical outcome have led to prophylactic and preemptive management strategies in patients at high risk. Classic high-risk populations include patients with chemotherapy-induced prolonged neutropenia in the setting of acute leukemia and allogeneic hematopoietic stem cell recipients with graft-versus-host disease. Prophylactic mode involves antifungal administration throughout the “at risk” period to prevent infection; published studies with posaconazole and to a much lesser extent, itraconazole, are of promise. However, many drawbacks of these triazoles preclude their liberal use. A preemptive approach involves serial screening of patients with the fungal biomarker, serum Aspergillus galactomannan, to identify early infection; this strategy may be initiated at the onset of the high-risk period or when there are clinical features suggestive of infection. Limited data available with this strategy in the neutropenic population are somewhat encouraging. Clearly, more refined diagnostic tools, improved “quantification” of risk for invasive aspergillosis in different subsets of patients, and direct comparative studies of the two strategies in different settings are needed. At present, prophylaxis against invasive aspergillosis with mold-active azoles may be reserved for those at the highest risk; for those at intermediate risk, prophylaxis with a yeast-active drug combined with the preemptive screening strategy is prudent.     

Performance of the (1,3)-Beta-d-Glucan Assay on Bronchoalveolar Lavage Fluid for the Diagnosis of Invasive Pulmonary Aspergillosis

Detection of (1,3)-beta-d-glucan (BDG), a component of the cell wall of many fungi, was studied in bronchoalveolar lavage fluid (BALF) as a possible aid for the diagnosis of proven/probable invasive pulmonary aspergillosis (IPA). BDG was measured on stored BALF from 13 patients with EORTC/MSGERC defined proven/probable IPA and 26 matched control patients without IPA. The median BALF BDG was 80 pg/mL (range <?45–8240 pg/mL) in the IPA cohort and 148 pg/mL (range <?45–5460 pg/mL) in the non-IPA cohort. Using a positive cutoff of?≥?80 pg/mL, sensitivity was 54% and specificity was 38%. Higher cutoff values led to improvement in specificity but a dramatic decrease in sensitivity. ROC/AUC analysis was unable to identify an optimal cutoff value at which test performance was enhanced: AUC 0.43, 95% CI 0.24–0.63. When the BDG assay was performed on BALF, neither sensitivity nor specificity was sufficient for use in the diagnosis of IPA.

     

Case Series Study of Invasive Pulmonary Aspergillosis

Diagnosis of invasive pulmonary aspergillosis (IPA) is challenging. The objective of the study was to assess the value of microbiological tests to the diagnosis of IPA in the absence of non-specific radiological data. A retrospective study of 23 patients with suspicion of IPA and positivity of some microbiological diagnostic tests was performed. These tests included conventional microbiological culture, detection of Aspergillus galactomannan (GM) antigen and in some patients (1 → 3)-β-d-glucan (BDG) and Aspergillus fumigatus DNA using the LightCycler^® SeptiFast test. In 10 patients with hematological malignancy, 6 cases were considered ‘probable’ and 4 ‘non-classifiable.’ In 8 patients with chronic lung disease, 7 cases were classified as ‘probable’ and 1 as ‘proven,’ and in 5 patients with prolonged ICU stay (>7 days), there were 2 ‘proven’ cases, 2 ‘non-classifiable’ and 1 putative case. Microbiological culture was positive in 17 cases and 18 Aspergillus spp. were isolated (one mixed culture). A. fumigatus was the most frequent (44.4%) followed by A. tubingensis. The Aspergillus galactomannan (GM) antigen assay was positive in 21 cases (91.3%). The GM antigen and the (1 → 3)-β-d-glucan (BDG) assays were both performed in 12 cases (52.2%), being positive in 9. The SeptiFast test was performed in 7 patients, being positive in 4. In patients with non-classifiable pulmonary aspergillosis and one or more positive microbiological tests, radiological criteria may not be considered a limiting factor for the diagnosis of IPA.     

Hypothermic Endpoint for an Intranasal Invasive Pulmonary Aspergillosis Mouse Model

Immunocompromised mice were infected intranasally with Aspergillus fumigatus as part of a vaccine efficacy study. Although body temperature was measured throughout the study, a formal evaluation of its usefulness as an endpoint criterion was not performed. We retrospectively evaluated survival data and temperature records to determine whether body temperature can be used as an objective predictor of death and included in the humane endpoint criteria for this mouse model. CF1 mice were immunosuppressed with either cortisone acetate or by treatment with antiGR1 (a neutrophil-depleting antibody) and then intranasally challenged with A. fumigatus. Body temperature was measured by using an infrared noncontact thermometer a maximum of 3 times daily until death or euthanasia. A surface body temperature below 29.0 °C was correlated with a poor chance of survival, and using this cutoff point with signs of morbidity (hunched, ruffled fur, respiratory distress) reliably indicates mice for euthanasia without negatively affecting data collection. Using 2 subsequent readings of less than 31.0 °C as an endpoint would have led to premature euthanasia of only one mouse (2.2%). As a single reading, a body temperature of 28.8 °C had a sensitivity of 92.2% and specificity of 90.9%. Hypothermia proved to be a useful addition to the humane endpoint criteria for this mouse model, and veterinary and research groups should discuss their study needs in relation to animal welfare to best determine the most appropriate means of including this parameter.Abbreviations: BT, body temperature; IPA, invasive pulmonary aspergillosis; ROC, receiver operator characteristicsAspergillus species ubiquitously inhabit the environment, and people inhale as many as a few hundred conidia daily.¹ The conidia of many Aspergillus species are relatively large and typically are deposited in the paranasal sinuses and upper airways, whereas A. fumigatus conidia are small enough to reach the pulmonary alveoli.¹ Although these conidia are essentially benign for healthy persons, those who are immunosuppressed can develop severe disease known as invasive pulmonary aspergillosis (IPA).⁸ This fungal disease is one of the most severe and often fatal complications associated with patients undergoing immunosuppressive treatment, such as those with hematologic malignancies who have received a hematopoietic cell transplant.³ Given the severe nature of IPA and the high mortality rate in this high-risk population, an animal model that accurately reflects the natural progression of the disease is imperative for vaccination and treatment studies.One of our investigators has been working on developing an A. fumigatus vaccine by using a murine model of aspergillosis. IPA is induced in immunosuppressed mice after intranasal inoculation. This model closely mimics the bronchopneumonia seen in human patients and therefore has historically been one of the more popular animal models for studying the disease.² Similar to the infection seen in humans, mice develop severe respiratory distress and have a high mortality rate. The mortality tends to be fairly acute, within 24 to 72 h after inoculation, and it can be very difficult to predict which mice will survive and which will eventually succumb to infection. The humane endpoints that the investigator had being using with this model were somewhat subjective. Given our goal to refine experiments as much as possible to enhance animal welfare and reduce animal suffering and morbidity, the veterinary care staff met with the investigative group in an attempt to further refine the endpoints and to include some objective criteria.Because hypothermia has been discussed as a quick and reliable indicator of mortality in several animal models,^{7,12,14-16,19-22} we investigated its use as a potential endpoint in our model. However, when looking through the literature, we were unable to find information on using body temperature (BT) measurements as a predictor of death in an animal model similar to our intranasal inoculation of Aspergillus. The publications we found mostly focused on bacterial^{12,13,15,19,20} or viral infections,^18,19,22 with only one fungal model that involved Candida albicans.^19,21 These studies recommended vastly different hypothermic endpoints, suggesting variation depending on the infectious agent, temperature recording device, and model used. For example, a study evaluating a staphylococcal enterotoxic shock model found that mice reaching a body temperature as low as 23.4 °C had an equal chance of dying or surviving,²⁰ whereas a model of influenza virus infection led to a hypothermic endpoint recommendation of 32 °C.²² The fungal infection model involved intravenous inoculation of Candida and recommended adopting an endpoint of 33.3 °C.²¹ However, the Candida study²¹ used a different fungal species and route of inoculation than did our IPA model. Given the variety of endpoints recommended for the various infectious diseases and animal models, we decided that data directly from our model were necessary to independently evaluate the usefulness of a hypothermic endpoint for our particular model of interest. BT measurements were already incorporated into the design of these studies, so we retrospectively analyzed the data in an attempt to identify a specific hypothermic endpoint for this murine model of IPA.     

Enzymatic Assays for the Diagnosis of Bradykinin-Dependent Angioedema

Background

The kinins (primarily bradykinin, BK) represent the mediators responsible for local increase of vascular permeability in hereditary angioedema (HAE), HAE I-II associated with alterations of the SERPING1 gene and HAE with normal C1-Inhibitor function (HAE-nC1INH). Besides C1-Inhibitor function and concentration, no biological assay of kinin metabolism is actually available to help physicians for the diagnosis of angioedema (AE). We describe enzymatic tests on the plasma for diagnosis of BK-dependent AE.

Methods

The plasma amidase assays are performed using the Pro-Phe-Arg-p-nitroanilide peptide substrate to evaluate the spontaneous amidase activity and the proenzyme activation. We analyzed data of 872 patients presenting with BK-dependent AE or BK-unrelated diseases, compared to 303 controls. Anti-high MW kininogen (HK) immunoblot was achieved to confirm HK cleavage in exemplary samples. Reproducibility, repeatability, limit of blank, limit of detection, precision, linearity and receiver operating characteristics (ROC) were used to calculate the diagnostic performance of the assays.

Results

Spontaneous amidase activity was significantly increased in all BK-dependent AE, associated with the acute phase of disease in HAE-nC1INH, but preserved in BK-unrelated disorders. The increase of the amidase activity was associated to HK proteolysis, indicating its relevance to identify kininogenase activity. The oestrogens, known for precipitating AE episodes, were found as triggers of enzymatic activity. Calculations from ROC curves gave the optimum diagnostic cut-off for women (9.3 nmol⋅min⁻¹⋅mL⁻¹, area under curve [AUC] 92.1%, sensitivity 80.0%, and specificity 90.1%) and for men (6.6 nmol·min⁻¹⋅mL⁻¹, AUC 91.0%, sensitivity 87.0% and specificity 81.2%).

Conclusion

The amidase assay represents a diagnostic tool to help physicians in the decision to distinguish between BK-related and –unrelated AE.     

Pathogenesis of Invasive Pulmonary Aspergillosis in Transplant Recipients

Purpose of Review

Transplant patients are at high risk for invasive pulmonary aspergillosis, and the associated mortality is high. The purpose of this study is to review the pathogenesis of invasive pulmonary aspergillosis (IPA) in transplant patients.

Recent Findings

The pathogenesis of aspergillosis is multifactorial and results from a complex interplay between the pathogen and host. It is well recognized that Aspergillus causes IPA in immunocompromised patients. Recent studies have shown that Aspergillus might also cause diseases likely attributed to an unmodulated immune response in certain transplant recipients such as bronchopulmonary aspergillosis or bronchiolitis obliterans syndrome in lung transplant recipients.

Summary

This review focuses on two crucial axes of the damage response framework applicable to aspergillosis: (1) Aspergillus virulence attributes that enable it to survive and proliferate in the host (thermotolerance, stress and hypoxic response, secretion of secondary metabolites) and (2) host response with specific focus on innate immunity and angiogenesis.

     

Chronic Invasive Sinus Aspergillosis in Immunocompetent Hosts: A Geographic Comparison

Purpose  

To investigate potential differences in clinical presentation, histopathology, and outcomes of chronic invasive sinus aspergillosis (CISA) based on geographic region and species of Aspergillus isolated.     

Development of a Prototype Lateral Flow Immunoassay (LFI) for the Rapid Diagnosis of Melioidosis

Burkholderia pseudomallei is a soil-dwelling bacterium and the causative agent of melioidosis. Isolation of B. pseudomallei from clinical samples is the “gold standard” for the diagnosis of melioidosis; results can take 3–7 days to produce. Alternatively, antibody-based tests have low specificity due to a high percentage of seropositive individuals in endemic areas. There is a clear need to develop a rapid point-of-care antigen detection assay for the diagnosis of melioidosis. Previously, we employed In vivo Microbial Antigen Discovery (InMAD) to identify potential B. pseudomallei diagnostic biomarkers. The B. pseudomallei capsular polysaccharide (CPS) and numerous protein antigens were identified as potential candidates. Here, we describe the development of a diagnostic immunoassay based on the detection of CPS. Following production of a CPS-specific monoclonal antibody (mAb), an antigen-capture immunoassay was developed to determine the concentration of CPS within a panel of melioidosis patient serum and urine samples. The same mAb was used to produce a prototype Active Melioidosis Detect Lateral Flow Immunoassay (AMD LFI); the limit of detection of the LFI for CPS is comparable to the antigen-capture immunoassay (∼0.2 ng/ml). The analytical reactivity (inclusivity) of the AMD LFI was 98.7% (76/77) when tested against a large panel of B. pseudomallei isolates. Analytical specificity (cross-reactivity) testing determined that 97.2% of B. pseudomallei near neighbor species (35/36) were not reactive. The non-reactive B. pseudomallei strain and the reactive near neighbor strain can be explained through genetic sequence analysis. Importantly, we show the AMD LFI is capable of detecting CPS in a variety of patient samples. The LFI is currently being evaluated in Thailand and Australia; the focus is to optimize and validate testing procedures on melioidosis patient samples prior to initiation of a large, multisite pre-clinical evaluation.